Friday, December 8, 2023, 3:15 PM – 5:15 PM PT (6:15 PM – 8:15 PM ET)

Beyond the Guidelines: Clinical Investigator Perspectives on the Management of Chronic Lymphocytic Leukemia (Part 3 of a 4-Part Series)

A CME Friday Satellite Symposium and Virtual Event Preceding the 65th ASH Annual Meeting

Omni San Diego Hotel
675 L Street
San Diego, CA 92101
Phone: (619) 231-6664

Program Schedule — Pacific Time
2:45 PM – 3:15 PM — Registration and Light Snacks
3:15 PM – 5:15 PM — Educational Meeting

Meeting Room
Grand Ballroom (Level 2)

This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in San Diego, preregistration is required as seating is limited.  
Farrukh T Awan, MD
Professor of Internal Medicine
Director of Lymphoid Malignancies Program
Harold C Simmons Comprehensive Cancer Center
The University of Texas
Southwestern Medical Center
Dallas, Texas

Matthew S Davids, MD, MMSc
Associate Professor of Medicine
Harvard Medical School
Director of Clinical Research
Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts

Stephen J Schuster, MD
Director, Lymphoma Program and Lymphoma Translational Research
Robert and Margarita Louis-Dreyfus Professor
in CLL and Lymphoma
Professor of Medicine, Hematology/Oncology
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania

William G Wierda, MD, PhD
Jane and John Justin Distinguished Chair in
Leukemia Research in Honor of Dr Elihu Estey
Section Chief, Chronic Lymphocytic Leukemia
Center Medical Director
Department of Leukemia
Division of Cancer Medicine
Executive Medical Director
Inpatient Medical Services
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Jennifer Woyach, MD
Division of Hematology
Department of Internal Medicine
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio

Neil Love, MD
Research To Practice
Miami, Florida

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, and Lilly.
Program Schedule — Pacific Time
2:45 PM – 3:15 PM — Registration and Light Snacks
3:15 PM – 5:15 PM — Educational Meeting

A detailed agenda will be available in the coming weeks.

MODULE 1: Front-Line Treatment for Chronic Lymphocytic Leukemia (CLL)

MODULE 2: Novel Strategies Combining Bruton Tyrosine Kinase (BTK) and Bcl-2 Inhibitors in CLL

MODULE 3: Optimal Management of Adverse Events with BTK and Bcl-2 Inhibitors; Considerations for Special Patient Populations

MODULE 4: Selection and Sequencing of Therapies for Relapsed/Refractory CLL

MODULE 5: Promising Investigational Agents and Strategies

Target Audience
This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of chronic lymphocytic leukemia.

Learning Objectives

  • Individualize the selection of systemic therapy for patients with newly diagnosed chronic lymphocytic leukemia (CLL), considering new research findings, clinical presentation, biomarker profile, coexisting medical conditions and patient preferences.
  • Appraise available Phase III data documenting the comparative efficacy and tolerability of first- and second-generation Bruton tyrosine kinase (BTK) inhibitors and consider the implications of these findings for clinical decision-making for patients with newly diagnosed or previously treated CLL.
  • Appreciate the scientific rationale for the investigation of combined BTK and Bcl-2 inhibition, and review recently presented data documenting the safety and efficacy of this strategy in patients with newly diagnosed CLL.
  • Analyze how age, performance status, prior therapeutic exposure and other biologic and disease related factors impact the selection and sequencing of therapy for patients with relapsed/refractory (R/R) CLL.
  • Implement a plan of care to recognize and manage side effects and toxicities associated with recently approved and emerging systemic therapies employed in the management of CLL.
  • Discuss available clinical research findings demonstrating the efficacy and safety of noncovalent BTK inhibitors in patients with CLL, and use this information to evaluate the potential role of these agents in individuals with R/R disease.
  • Evaluate the biologic rationale for the investigation of CD19-directed chimeric antigen receptor T-cell therapy in patients with CLL, and identify individuals potentially appropriate for ongoing studies investigating this therapeutic strategy.
  • Recall available and emerging data with novel agents and combination strategies currently under investigation in CLL and, where applicable, refer eligible patients for clinical trial participation.

CME Credit Form
A CME credit link will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY— Faculty panel disclosures to be provided.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, and Lilly.

Omni San Diego Hotel
675 L Street
San Diego, CA 92101
Phone: (619) 231-6664

Meeting Room
Grand Ballroom (Level 2)

Located directly across from the San Diego Convention Center, where the 2023 ASH Annual Meeting is taking place.

This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of chronic lymphocytic leukemia.

There is no fee to participate in this hybrid event. For the in-person symposium in San Diego preregistration is required as seating is limited.

NOTICE: Registration for this event is independent of registration for the ASH Annual Meeting.

IN-PERSON Registration for clinicians in practice/healthcare professionals

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

IN PERSON Registration
for clinicians»
IN-PERSON Registration for other/industry professionals*

Please note, a limited number of seats are available to other/industry professionals on a first come, first served basis

IN PERSON Registration
for non-clinicians »
* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
LIVE WEBCAST Registration for all professionals

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.

If you have any questions, please feel free to contact us via email at, or call (800) 233-6153.